These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 33199209)

  • 1. PD-L1 and B7-1 Cis-Interaction: New Mechanisms in Immune Checkpoints and Immunotherapies.
    Nishimura CD; Pulanco MC; Cui W; Lu L; Zang X
    Trends Mol Med; 2021 Mar; 27(3):207-219. PubMed ID: 33199209
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PD-L1:CD80 Cis-Heterodimer Triggers the Co-stimulatory Receptor CD28 While Repressing the Inhibitory PD-1 and CTLA-4 Pathways.
    Zhao Y; Lee CK; Lin CH; Gassen RB; Xu X; Huang Z; Xiao C; Bonorino C; Lu LF; Bui JD; Hui E
    Immunity; 2019 Dec; 51(6):1059-1073.e9. PubMed ID: 31757674
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer.
    Zhang H; Dai Z; Wu W; Wang Z; Zhang N; Zhang L; Zeng WJ; Liu Z; Cheng Q
    J Exp Clin Cancer Res; 2021 Jun; 40(1):184. PubMed ID: 34088360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy.
    Blank C; Gajewski TF; Mackensen A
    Cancer Immunol Immunother; 2005 Apr; 54(4):307-14. PubMed ID: 15599732
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Recent advancements in the B7/CD28 immune checkpoint families: new biology and clinical therapeutic strategies.
    Pulanco MC; Madsen AT; Tanwar A; Corrigan DT; Zang X
    Cell Mol Immunol; 2023 Jul; 20(7):694-713. PubMed ID: 37069229
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PD-1, PD-L1 (B7-H1) and Tumor-Site Immune Modulation Therapy: The Historical Perspective.
    Wang J; Yuan R; Song W; Sun J; Liu D; Li Z
    J Hematol Oncol; 2017 Jan; 10(1):34. PubMed ID: 28122590
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The efficacy of PD-1/PD-L1 blockade in cold cancers and future perspectives.
    Majidpoor J; Mortezaee K
    Clin Immunol; 2021 May; 226():108707. PubMed ID: 33662590
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Programmed cell death-1/programmed cell death ligand-1 checkpoint inhibitors: differences in mechanism of action.
    Zhang N; Tu J; Wang X; Chu Q
    Immunotherapy; 2019 Apr; 11(5):429-441. PubMed ID: 30698054
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A computational study of co-inhibitory immune complex assembly at the interface between T cells and antigen presenting cells.
    Su Z; Dhusia K; Wu Y
    PLoS Comput Biol; 2021 Mar; 17(3):e1008825. PubMed ID: 33684103
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PD-L1 Binds to B7-1 Only
    Chaudhri A; Xiao Y; Klee AN; Wang X; Zhu B; Freeman GJ
    Cancer Immunol Res; 2018 Aug; 6(8):921-929. PubMed ID: 29871885
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune Checkpoint PD-1/PD-L1: Is There Life Beyond Antibodies?
    Konstantinidou M; Zarganes-Tzitzikas T; Magiera-Mularz K; Holak TA; Dömling A
    Angew Chem Int Ed Engl; 2018 Apr; 57(18):4840-4848. PubMed ID: 29178534
    [TBL] [Abstract][Full Text] [Related]  

  • 12. PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations.
    Jiang Y; Chen M; Nie H; Yuan Y
    Hum Vaccin Immunother; 2019; 15(5):1111-1122. PubMed ID: 30888929
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Control of peripheral T-cell tolerance and autoimmunity via the CTLA-4 and PD-1 pathways.
    Fife BT; Bluestone JA
    Immunol Rev; 2008 Aug; 224():166-82. PubMed ID: 18759926
    [TBL] [Abstract][Full Text] [Related]  

  • 14. T cell checkpoint regulators in the heart.
    Grabie N; Lichtman AH; Padera R
    Cardiovasc Res; 2019 Apr; 115(5):869-877. PubMed ID: 30721928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Analysis of the role of negative T cell costimulatory pathways in CD4 and CD8 T cell-mediated alloimmune responses in vivo.
    Ito T; Ueno T; Clarkson MR; Yuan X; Jurewicz MM; Yagita H; Azuma M; Sharpe AH; Auchincloss H; Sayegh MH; Najafian N
    J Immunol; 2005 Jun; 174(11):6648-56. PubMed ID: 15905503
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunomodulatory role for MicroRNAs: Regulation of PD-1/PD-L1 and CTLA-4 immune checkpoints expression.
    Skafi N; Fayyad-Kazan M; Badran B
    Gene; 2020 Sep; 754():144888. PubMed ID: 32544493
    [TBL] [Abstract][Full Text] [Related]  

  • 17. High PD-1/PD-L1 Checkpoint Interaction Infers Tumor Selection and Therapeutic Sensitivity to Anti-PD-1/PD-L1 Treatment.
    Sánchez-Magraner L; Miles J; Baker CL; Applebee CJ; Lee DJ; Elsheikh S; Lashin S; Withers K; Watts AG; Parry R; Edmead C; Lopez JI; Mehta R; Italiano A; Ward SG; Parker PJ; Larijani B
    Cancer Res; 2020 Oct; 80(19):4244-4257. PubMed ID: 32855204
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comprehensive insights into the effects and regulatory mechanisms of immune cells expressing programmed death-1/programmed death ligand 1 in solid tumors.
    Liu M; Sun Q; Wei F; Ren X
    Cancer Biol Med; 2020 Aug; 17(3):626-639. PubMed ID: 32944395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The programmed death-1 ligand 1:B7-1 pathway restrains diabetogenic effector T cells in vivo.
    Paterson AM; Brown KE; Keir ME; Vanguri VK; Riella LV; Chandraker A; Sayegh MH; Blazar BR; Freeman GJ; Sharpe AH
    J Immunol; 2011 Aug; 187(3):1097-105. PubMed ID: 21697456
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New expression of PD-L1 on activated CD4
    Mazerolles F
    Hum Immunol; 2024 Jul; 85(4):110831. PubMed ID: 38870593
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.